Latest news
CardiNor AS and its partners Bioventix Ltd, Kaivogen Oy and Akershus University hospital have been granted Eurostars funding of the project: Secretoneurin, a breakthrough blood biomarker for heart disease and Sudden Cardiac Arrest risk. The total funding by EU is € 631,000. The Eurostars project will support the following important milestones for the company: Development and optimization of a simple test for measuring SN in the blood – Clinical validation using a very comprehensive patient material, this will also support and facilitate future CE marking – Optimization of assay production that will enable rapid commercialization.
Press releases
2016
New Data Supports Correlation Between Secretoneurin and Cardiovascular Disease
2015
CardiNor receives USD 0.75M to develop “missing link” CV risk test.
In the media
Unicard, 17.11.2016: (secretoneurin predicts mortality in patients with acute respiratory failure. Article in Norwegian)
Scientific Nordic, 02.10.2015:
Unicard, 12.03.2015:
VG, 27.09.2015: